Scienture (NASDAQ:SCNX), a specialty pharmaceutical company focused on developing and commercializing innovative therapies for underserved patient populations, today reported its financial results for the full year ended December 31, 2025.
The company’s performance was characterized by a rapid acceleration in top-line growth and a transformative expansion of its margin profile following the successful commercial introduction of its lead product, Arbli™.
For the full year 2025, Scienture reported net revenue of $431,609, representing a 216% increase compared to the prior year.
The revenue surge was accompanied by an unprecedented 7,240 basis point expansion in gross margin, which reached 76.8%.
This dramatic improvement reflects the high-margin nature of the company’s proprietary product portfolio and the operational efficiencies achieved as its commercial manufacturing transitioned to scale.
Despite the robust operational growth, the company reported a net loss from continuing operations of $41.5 million.
The bottom line was heavily impacted by a $26.3 million one-time, non-cash impairment charge recorded during the year.
As of December 31, 2025, Scienture maintained a cash balance of $6.7 million and reported positive working capital of $5.2 million, providing the necessary liquidity to support its ongoing commercial activities.
On the operational front, Scienture achieved several critical milestones to secure long-term market access for its core assets, Arbli™ and REZENOPY™.
The company successfully executed multiple agreements with major Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs), while securing favorable formulary placements.
Furthermore, Scienture strengthened its intellectual property position by obtaining patents for both products that are eligible for listing in the FDA’s Orange Book.